Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.03 -0.65%

-$0.02 today

Market cap
$103.75M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.01M

Average 0.04M

CLLS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Cellectis S.A.NASDAQ: CLLS

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit dips below year-ago levels

Q1 FY2026 gross profit of $1.25M fell 85.6% year over year, behind the +43.8% change in trailing-twelve-month gross profit. Sequentially, it fell 83.1% from the prior quarter. Over 3 fiscal years it compounded at +80.8% a year.

Context

  • Gross profit amounted to 86.6% of revenue in FY2025, up 8.7 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -85.6% toward the trailing-twelve-month pace of +43.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.25M-83.1% QoQ
Last fiscal yearDec 2025
$63.15M+95.4% YoY
LTMMar 2026
$55.76M+43.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-85.6%——
1 year+95.4%——
3-year CAGR+80.8%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
63.15M USD
Year-over-year change
+95.4%
4-year CAGR
+22.0%

Gross Profit vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +43.8% is the 3rd highest of 7, against a peer median of -54.4%.
  • Gross profit amounts to 81.9% of revenue for CLLS, versus a peer median of 73.2%.
CLLS Competitors
Gross Profit for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$112.77M USD+52.6%-20.7%52.5%
CLLSCellectis S.A.LTM Mar 2026$55.76M USD+43.8%+80.8%81.9%
ACIUAC Immune S.A.LTM Mar 2026CHF 3.7M CHF-86.9%-3.2%100.0%
KRROKorro Bio, Inc.LTM Mar 2026$2.81M USD-41.7%—73.2%
SLNSilence Therapeutics plcLTM Mar 2026$612.12K USD—-62.8%66.4%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$0 USD———
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$66.6K USD———
ANROAlto Neuroscience, Inc.LTM Mar 2026-$284K USD-67.1%——
MREOMereo BioPharma Group plcLTM Mar 2026-$528.63K USD+51.3%+12.5%105.7%
DBVTDBV Technologies S.A.LTM Mar 2026-$17.4M USD-146.9%——
Peer median (excluding CLLS) —-54.4%-11.9%73.2%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.